Literature DB >> 26355142

Inaccuracy of ICD-9 Codes for Chronic Kidney Disease: A Study from Two Practice-based Research Networks (PBRNs).

Charlotte W Cipparone1, Matthew Withiam-Leitch2, Kim S Kimminau2, Chet H Fox2, Ranjit Singh2, Linda Kahn2.   

Abstract

BACKGROUND: Inaccurate use of International Classification of Diseases, Ninth Revision (ICD-9), codes obfuscates registries used for research, resulting in unreliable data and inaccurate measurement of outcomes, and it may contribute to mismanagement of patients. Thus it is important to understand the prevalence of ICD-9 code misuse. We chose chronic kidney disease (CKD) as a condition of interest after several patients recruited for a previous study indicated they did not have the disease, despite the presence of the ICD-9 code (585.x) in their electronic medical record (EMR).
METHODS: Retrospective chart review of patients with the ICD-9 code for CKD stage 3 (585.3; n = 325). Data were collected from EMRs at 3 primary care practices Buffalo, New York (n = 2), and Kansas City, Kansas (n = 1).
RESULTS: Across all practices, 47% of patients with the CKD ICD-9 code did not have clinical indicators for the disease, based on Kidney Disease Outcomes Quality Initiative guidelines.
CONCLUSIONS: The CKD stage 3 ICD-9 code usage did not accurately reflect the prevalence of disease among this population. This has clinical implications because patients may be treated or receive tests for a disease they do not have. This also presents an important issue for research projects that rely on accurate data from EMRs to identify and recruit patients. © Copyright 2015 by the American Board of Family Medicine.

Entities:  

Keywords:  Chronic Disease; Chronic Kidney Diseases; Clinical Coding; Diagnostic Errors; Electronic Medical Records; Medical Errors

Mesh:

Year:  2015        PMID: 26355142     DOI: 10.3122/jabfm.2015.05.140136

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  9 in total

1.  Leveraging Big Data to Transform Drug Discovery.

Authors:  Benjamin S Glicksberg; Li Li; Rong Chen; Joel Dudley; Bin Chen
Journal:  Methods Mol Biol       Date:  2019

2.  Identification of adults with congenital heart disease of moderate or great complexity from administrative data.

Authors:  Jill M Steiner; James N Kirkpatrick; Susan R Heckbert; Asma Habib; James Sibley; William Lober; J Randall Curtis
Journal:  Congenit Heart Dis       Date:  2017-07-24       Impact factor: 2.007

3.  Disparities in Hypertension Control Across and Within Three Health Systems Participating in a Data-Sharing Collaborative.

Authors:  Kevin Selby; Martha Michel; Ginny Gildengorin; Leah Karliner; Rajiv Pramanik; Valy Fontil; Michael B Potter
Journal:  J Am Board Fam Med       Date:  2018 Nov-Dec       Impact factor: 2.657

4.  sureLDA: A multidisease automated phenotyping method for the electronic health record.

Authors:  Yuri Ahuja; Doudou Zhou; Zeling He; Jiehuan Sun; Victor M Castro; Vivian Gainer; Shawn N Murphy; Chuan Hong; Tianxi Cai
Journal:  J Am Med Inform Assoc       Date:  2020-08-01       Impact factor: 4.497

Review 5.  Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS.

Authors:  Lisa Bastarache
Journal:  Annu Rev Biomed Data Sci       Date:  2021-07-20

6.  A semi-supervised adaptive Markov Gaussian embedding process (SAMGEP) for prediction of phenotype event times using the electronic health record.

Authors:  Yuri Ahuja; Jun Wen; Chuan Hong; Zongqi Xia; Sicong Huang; Tianxi Cai
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

7.  Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.

Authors:  Gregory A Nichols; Anastasia Ustyugova; Anouk Déruaz-Luyet; Maureen O'Keeffe-Rosetti; Kimberly G Brodovicz
Journal:  J Am Soc Nephrol       Date:  2020-06-02       Impact factor: 10.121

8.  Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort.

Authors:  John Sy; Jiu-Ting Hsiung; Drake Edgett; Kamyar Kalantar-Zadeh; Elani Streja; Wei Ling Lau
Journal:  Am J Nephrol       Date:  2021-03-31       Impact factor: 3.754

9.  Can billing codes accurately identify rapidly progressing stage 3 and stage 4 chronic kidney disease patients: a diagnostic test study.

Authors:  Kabir Jalal; Edwin J Anand; Rocco Venuto; Joe Eberle; Pradeep Arora
Journal:  BMC Nephrol       Date:  2019-07-12       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.